This move is archived. Current quotes and coverage live on the stock page.
Get MSCL alerts:
Satellos Bioscience Inc. (MSCL.TO) saw its stock price drop by 1.60% in the last trading session, closing at CA$8.00. This decline occurred without any significant news or events to explain it, leaving investors concerned about the company's stability and future.
Investor takeaway: Investors should be cautious, as this recent drop may signal underlying issues that need attention, especially given the company's ambitious clinical programs.
Advertisement
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$264.14M
52W high
$18.98
52W low
$7.32
1W change
-4.20%
Beta
1.14
Analyst Price Targets
Based on analyst covering MSCL
Wall Street analysts forecast MSCL stock price to rise 41.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.67
+41.0% Upside
Current Price
C$12.53
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
46.3%
Annualized
90-Day Vol
74.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$14.98
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$13.30 | C$11.33 โ C$15.60 |
| 60 trading days | C$14.11 | C$11.26 โ C$17.70 |
| 90 trading days | C$14.98 | C$11.36 โ C$19.76 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Satellos Bioscience Inc. stock drops to CA$8.00
The stock's market cap is now CA$169.36 million, reflecting investor worries as it continues to face downward pressure.
Bull case
Satellos is making progress with its clinical programs, including the BASECAMP Phase 2 trial for SAT-3247. If successful, this could lead to significant advancements in treating Duchenne muscular dystrophy.
Bear case
The recent stock performance highlights investor uncertainty, particularly due to the lack of news supporting its valuation. Without renewed confidence, the stock could face further declines.
Understanding the Decline
Advertisement
Satellos Bioscience's stock price has dropped to CA$8.00, down 1.60%. This decline comes without any recent announcements that could clarify the situation, leaving investors questioning the company's market position. The absence of news often leads to speculation and uncertainty, which may be affecting the stock's performance.
Future Prospects
Despite the current downturn, Satellos is focused on advancing its clinical programs, especially the BASECAMP Phase 2 trial for SAT-3247. If these initiatives succeed, they could significantly benefit the company and its shareholders. However, the market's reaction suggests that investors are skeptical about the company's ability to deliver on these promises.
Investor Sentiment
The recent performance of Satellos Bioscience Inc. reflects a cautious sentiment among investors. With a market cap of CA$169.36 million and no dividends or profits reported, the stock's decline raises concerns about its long-term viability. Investors should keep a close eye on developments as the company progresses with its clinical trials and works to regain market confidence.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
